Group 1: Market Overview - The Hang Seng Index rose by 0.62%, while the Hang Seng Tech Index increased by 0.82%, with a total turnover of HKD 124.6 billion in the morning session [1] - The Hang Seng Biotechnology Index surged by 3.1%, driven by optimism in the innovative drug sector ahead of the 2025 World Lung Cancer Conference, indicating potential for valuation recovery [1] Group 2: Company Performances - Three-Six Pharmaceutical (01530) saw a significant increase of 9.6% [1] - Hengrui Medicine-B (02142) rose by 5.82% [1] - Hutchison China MediTech (00013) increased by 6% [1] - United Laboratories (03933) gained 5% [1] - WuXi Biologics (02269) rose by 4.17% [1] Group 3: Other Notable Stocks - Chow Tai Fook (06168) surged over 13% as the gold consumption market enters a peak season, with expectations of inclusion in the Hong Kong Stock Connect [2] - FunPlus (09890) increased by over 5% after completing a name change and upgrading its overseas brand integration, with a higher proportion of overseas revenue in the first half [2] - Lehua Entertainment (02306) rose by 16%, with a nearly 90% year-on-year increase in interim profit attributable to shareholders, expanding monetization channels for its trendy IP [3] - UBTECH Robotics (09880) increased by 3%, with humanoid robot orders reaching CNY 400 million and securing a USD 1 billion strategic investment from a Middle Eastern fund [4] - Mobi Development (01860) surged over 12%, hitting a historical high with a cumulative increase of over 110% this year [5] - Goldwind Technology (02208) rose over 10%, reaching a new high as the wind power sector experiences accelerated growth, leading the industry in gross margin improvement [5] - Zhongshen Jianye (02503) experienced a significant drop, falling over 74% to a historical low, with a loss of CNY 11.81 million in the first half [5]

Group 1: Market Performance - The Hang Seng Index rose by 0.62%, while the Hang Seng Tech Index increased by 0.82%, with a total turnover of HKD 124.6 billion in the morning session [1] - The Hang Seng Biotechnology Index surged by 3.1%, driven by optimism in the innovative drug sector ahead of the 2025 World Lung Cancer Conference [1] Group 2: Notable Stock Movements - Three-Sixty Biopharmaceuticals (01530) saw a significant increase of 9.6%, while Hengrui Medicine-B (02142) rose by 5.82%, and Hutchison China MediTech (00013) increased by 6% [1] - The stock of Chow Tai Fook (06168) jumped over 13%, with attention on the upcoming peak gold consumption season and potential inclusion in the Hong Kong Stock Connect [1] - The stock of FunPlus (09890) rose over 5% after completing a name change and upgrading its overseas brand integration, with an increase in overseas revenue proportion [1] - Lehua Entertainment (02306) surged by 16%, reporting a nearly 90% year-on-year increase in interim profit attributable to shareholders, expanding monetization channels through IP incubation [1] - UBTECH Robotics (09880) increased by 3%, with humanoid robot orders reaching CNY 400 million and securing USD 1 billion in strategic financing from a Middle Eastern fund [1] - Hui Liang Technology (01860) rose over 12%, hitting a historical high, with a cumulative increase of over 110% in stock price this year [1] - Goldwind Technology (002202) (02208) increased by over 10%, reaching a new high, with the wind power sector experiencing accelerated growth and leading the industry in gross margin improvement [1] Group 3: Company Challenges - Zhongshen Jianye (02503) experienced a significant drop, falling over 74% to reach a historical low, with a transition from profit to a loss of CNY 11.81 million in the first half of the year [2]

Group 1 - The core viewpoint is that the innovative drug sector is experiencing a significant rise, with multiple companies showing substantial stock price increases ahead of the World Lung Cancer Conference in September 2025, where major product launches are expected [1] - Companies such as 3SBio, Hengrui Medicine, and WuXi Biologics have seen stock price increases of 9.55%, 2.95%, and 5.16% respectively, indicating strong market interest [1] - The upcoming conference is anticipated to provide new development opportunities and market attention for innovative drug companies through the release and exchange of research results [1] Group 2 - In the first seven months of this year, China's innovative drug companies have normalized their business development (BD) overseas, with license out amounts reaching nearly $80 billion, a year-on-year increase of over 160% [2] - Analysts suggest that the essence of Chinese innovative drugs going global in 2025 is to replace some ecological niches of overseas biotech through national advantages, potentially leading to new breakthroughs in the global innovative drug industry [2] - The deep participation of Chinese innovative drugs in the global industrial chain is expected to benefit significantly from the global innovation cycle, especially if a new round of interest rate cuts occurs overseas [2]

Group 1 - The core viewpoint is that the innovative drug sector is experiencing a significant upward trend, with multiple companies showing substantial stock price increases ahead of the 2025 World Lung Cancer Conference [1] - Notable stock price increases include: 9.55% for 3SBio, 6.25% for Hengrui Medicine, and 5.16% for WuXi Biologics, indicating strong market interest [1] - The upcoming conference in Barcelona is expected to provide new development opportunities and market attention for innovative drug companies through the release of significant new products [1] Group 2 - In the first seven months of the year, China's innovative drug companies have seen a normalization in business development (BD) overseas, with license out amounts nearing $80 billion, a year-on-year increase of over 160% [2] - Analysts suggest that the essence of China's innovative drug overseas expansion is to replace certain ecological niches of foreign biotech companies, potentially leading to new breakthroughs in the global innovative drug industry [2] - The deep participation of Chinese innovative drugs in the global supply chain is expected to benefit significantly from the global innovation cycle [2]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) shares rose over 5%, currently at 24.68 HKD with a trading volume of 112 million HKD, following the announcement of upcoming data presentations at major oncology conferences in 2025 [1] Group 1: Upcoming Events - The company will present updated research data on its proprietary compounds at the 2025 World Lung Cancer Conference (WCLC) in Barcelona from September 6 to 9, and at the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China from September 10 to 14 [1] Group 2: Research Highlights - The latest analysis results of the SACHI and SAVANNAH studies, as well as a Phase IIIb confirmatory study of Savolitinib (赛沃替尼), will be presented at the WCLC. Savolitinib is a potent and selective oral MET tyrosine kinase inhibitor co-developed by AstraZeneca and Hutchison China MediTech [1] - The first human Phase I clinical trial data of HMPL-653, a novel, selective, and potent CSF-1R inhibitor, in patients with tenosynovial giant cell tumors will be unveiled at the CSCO annual meeting [1]

Core Viewpoint - Hutchison China MediTech (00013) saw a stock increase of over 5%, reaching HKD 24.68 with a trading volume of HKD 112 million, following the announcement of upcoming data presentations at major oncology conferences in 2025 [1] Group 1: Upcoming Events - The company will present updated research data on its proprietary compounds at the 2025 World Lung Cancer Conference (WCLC) in Barcelona from September 6 to 9, and at the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China, from September 10 to 14 [1] Group 2: Research Highlights - The latest analysis results of the SACHI and SAVANNAH studies, as well as a Phase IIIb confirmatory study of Savolitinib for non-small cell lung cancer, will be disclosed at the WCLC [1] - HMPL-653, a novel selective and potent CSF-1R inhibitor, will have its first human Phase I clinical trial data in Chinese patients with tenosynovial giant cell tumors presented at the CSCO annual meeting [1]

Core Insights - Hutchison China MediTech Limited (Chi-Med) will present updated data on several of its self-developed compounds at the 2025 World Lung Cancer Conference (WCLC) in Barcelona and the 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) in Jinan, China [1] Group 1: Upcoming Conferences - The 2025 WCLC will take place from September 6 to 9 in Barcelona, Spain [1] - The 2025 CSCO Annual Meeting will be held from September 10 to 14 in Jinan, China [1] Group 2: Research Highlights - The latest analysis results of the SACHI and SAVANNAH studies, as well as a Phase IIIb confirmatory study of Savolitinib for treating non-small cell lung cancer, will be presented at the WCLC [1] - Savolitinib is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI) co-developed by AstraZeneca and Chi-Med, with commercialization by AstraZeneca [1] - Data from the first human Phase I clinical trial of HMPL-653, a novel, selective, and potent CSF-1R inhibitor, in patients with tenosynovial giant cell tumors will be presented for the first time at the CSCO Annual Meeting [1]

Core Viewpoint - Hutchison China MediTech Limited (和黄医药) will present updated research findings on its self-developed compounds at two major conferences in 2025, highlighting its ongoing commitment to advancing cancer treatment [1] Group 1: Upcoming Conferences - The 2025 World Lung Cancer Conference (WCLC) will take place in Barcelona, Spain from September 6 to 9, 2025 [1] - The 2025 Annual Meeting of the Chinese Society of Clinical Oncology (CSCO) will be held in Jinan, China from September 10 to 14, 2025 [1] Group 2: Research Focus - The latest analysis results of the SACHI study, SAVANNAH study, and an Ib phase validation study on Savolitinib for treating non-small cell lung cancer will be presented at the WCLC [1] - Savolitinib is described as a potent and highly selective oral MET tyrosine kinase inhibitor (TKI), co-developed by AstraZeneca and Hutchison China MediTech, with commercialization handled by AstraZeneca [1]

Core Insights - Hutchison China MediTech Limited (HCM) will present updated data on its proprietary compounds at two major conferences in September 2025, specifically the World Lung Cancer Conference (WCLC) in Barcelona and the Chinese Society of Clinical Oncology (CSCO) annual meeting in Jinan, China [1] Group 1: Upcoming Presentations - HCM will showcase the latest analysis results of the SACHI and SAVANNAH studies, as well as a Phase IIIb confirmatory study of Savolitinib for the treatment of non-small cell lung cancer at the WCLC [1] - The first human Phase I clinical trial data for HMPL-653, a novel selective and potent CSF-1R inhibitor, will be presented at the CSCO annual meeting [1] Group 2: Drug Development - Savolitinib is described as a potent and highly selective oral MET tyrosine kinase inhibitor (TKI), co-developed by AstraZeneca and HCM, with AstraZeneca responsible for commercialization [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不 對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HUTCHMED (China) Limited 和黃醫藥（中國）有限公司 （於開曼群島註冊成立的有限公司） （股份代號：13） | 摘要標題 | 報告人/ 主要作者 | 報告詳情 | | --- | --- | --- | | 研究者發起的研究 | | | | 索凡替尼、度伐利尤單抗聯合化療用於一線治療廣泛期小細胞肺癌的療效及 | 張卉/ 胡瑛，北京胸科 | P3.13.22 | | 安全性 | 醫院，中國北京 | 海報展示 Poster: Small Cell Lung | | Efficacy and Safety of Surufatinib, Durvalumab in Combined with | | Cancer and Neuroendocrine | | Chemotherapy as First-line Treatment of Extensive-stage Small-cell ...